ReviewClinical biochemistry2013
Quality assessment for clinical proteomics.
Review in Clinical biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Review
- Mass spectrometry-based proteomics of FFPE tissues: progress, limitations, and clinical translation barriers.Clinical proteomics · 2025Review
- Multicenter Longitudinal Quality Assessment of MS-Based Proteomics in Plasma and Serum.Journal of proteome research · 2025Article
- A Framework for Quality Control in Quantitative Proteomics.Journal of proteome research · 2024Article
- Quality Control in the Mass Spectrometry Proteomics Core: A Practical Primer.Journal of biomolecular techniques : JBT · 2024Article
- A framework for quality control in quantitative proteomics.bioRxiv : the preprint server for biology · 2024Article
- Establishing Quality Control Procedures for Large-Scale Plasma Proteomics Analyses.Journal of the American Society for Mass Spectrometry · 2023Article
- A Review of the Scientific Rigor, Reproducibility, and Transparency Studies Conducted by the ABRF Research Groups.Journal of biomolecular techniques : JBT · 2020Review
- Article
- The Human Ovary and Future of Fertility Assessment in the Post-Genome Era.International journal of molecular sciences · 2019Review
- Proteomics and phosphoproteomics in precision medicine: applications and challenges.Briefings in bioinformatics · 2019Review
- Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.Journal of ovarian research · 2018Review
- Promise and Implementation of Proteomic Prostate Cancer Biomarkers.Diagnostics (Basel, Switzerland) · 2018Review
- Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers.Frontiers in genetics · 2018Article
- QCloud: A cloud-based quality control system for mass spectrometry-based proteomics laboratories.PloS one · 2018Article
- Optimizing High-Resolution Mass Spectrometry for the Identification of Low-Abundance Post-Translational Modifications of Intact Proteins.Journal of proteome research · 2017Article
- A Golden Age for Working with Public Proteomics Data.Trends in biochemical sciences · 2017Review
- Heterologous fibrin sealant derived from snake venom: from bench to bedside - an overview.The journal of venomous animals and toxins including tropical diseases · 2017Review
- The diverse and expanding role of mass spectrometry in structural and molecular biology.The EMBO journal · 2016Review
- An Automated Pipeline to Monitor System Performance in Liquid Chromatography-Tandem Mass Spectrometry Proteomic Experiments.Journal of proteome research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Proteomics has emerged from the labs of technologists to enter widespread application in clinical contexts. This transition, however, has been hindered by overstated early claims of accuracy, concerns about reproducibility, and the challenges of handling batch effects properly. New efforts have produced sets of performance metrics and measurements of variability that establish sound expectations for experiments in clinical proteomics. As researchers begin incorporating these metrics in a quality by design paradigm, the variability of individual steps in experimental pipelines will be reduced, regularizing overall outcomes. This review discusses the evolution of quality assessment in 2D gel electrophoresis, mass spectrometry-based proteomic profiling, tandem mass spectrometry-based protein inventories, and proteomic quantitation. Taken together, the advances in each of these technologies are establishing databases that will be increasingly useful for decision-making in clinical experimentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.